Fresenius Medical Care AG & Co. (FMS)
(Delayed Data from NYSE)
$21.04 USD
+0.33 (1.59%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $21.05 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.04 USD
+0.33 (1.59%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $21.05 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
New Strong Sell Stocks for October 14th
by Zacks Equity Research
ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.
Fresenius Medical's (FMS) Deal to Boost Home Dialysis in Japan
by Zacks Equity Research
Fresenius Medical (FMS) partners with JMS Co. Ltd. to provide innovative home dialysis therapies to the aging population in Japan to improve their wellbeing.
Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the second quarter despite ongoing pandemic-led higher PPE costs.
Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System
by Zacks Equity Research
Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.
Fresenius Medical's (FMS) Training Center to Boost Patient Care
by Zacks Equity Research
Fresenius Medical (FMS) inaugurates new training center in Korea to help in the improvement of patient care by offering comprehensive education programs for healthcare professionals.
DaVita's (DVA) Deal to Aid Patients in Kidney Transplantation
by Zacks Equity Research
DaVita (DVA) and NKF collaborate to help kidney patients seeking a living donor, thereby improving health equity in kidney transplant process.
Fresenius Medical (FMS) Gains 1.1% Since Q1 Earnings Beat
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from organic growth in Health Care Products segment, and performance in Asia Pacific.
DaVita (DVA) Partners With Fresenius, Boost Home Dialysis Care
by Zacks Equity Research
DaVita's (DVA) recent collaboration will help patients benefit from the portability, dependability and flexibility of NxStage home machines, designed to be easy to use.
Fresenius Medical (FMS) Q4 Earnings Beat, Revenues Miss
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.
The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics
Is Fresenius (FMS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 MedTech Underperformers Poised for a Turnaround in 2021
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.
Is Fresenius (FMS) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Fresenius (FMS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Are Investors Undervaluing Fresenius (FMS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Fresenius Medical (FMS) Stock
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.
Is Fresenius Medical Care (FMS) a Good Stock to Pick Now?
by Zacks Equity Research
Is Fresenius Medical Care (FMS) a great pick from the value investor's perspective right now? Read on to know more.
Fresenius Medical (FMS) Stock Gains 5.6% on Q3 Earnings Beat
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter earnings benefit from stable segmental performance.
Here's Why You Should Retain Fresenius Medical Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.
Should Value Investors Buy Fresenius (FMS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FMS vs. SMLR: Which Stock Is the Better Value Option?
by Zacks Equity Research
FMS vs. SMLR: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: FMS, HOLX and TMO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: FMS, HOLX and TMO
3 MedTech Outperformers to Grab Amid September Pullback
by Trina Mukherjee
Let's grab these three stocks that have continued to show tremendous promise despite market volatility resulting from the coronavirus pandemic.
5 Top PEG-Driven Value Stocks Amid Coronavirus-Led Selloffs
by Urmimala Biswas
While searching for a suitable value investment option, investors are unlikely to consider PEG ratio among a number of other popular value metrics.
Buy 4 Beaten-Down MedTech Value Stocks Amid September Selloffs
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.